Clinical safety of tocilizumab in rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 10, Issue 1, 2011, Pages 123-131

  Bannwarth, Bernard ^a   Richez, Christophe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

DMARDs; drug induced adverse events; humanized anti IL 6 receptor antibody; safety; tocilizumab

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; METHOTREXATE; TOCILIZUMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CELLULITIS; CLINICAL EVALUATION; CREATININE CLEARANCE; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; HERPES VIRUS INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOPENIA; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MONOTHERAPY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG TOXICITY; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650464387     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.537256     Document Type: Article

References (32)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373: 659-72 . An update of the pathogenesis of RA and its therapeutic implications.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72 . An update of the pathogenesis of RA and its therapeutic implications.
3. Van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41
4. Moots RJ, Ostor AJK, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission? Expert Opin Investig Drugs 2009;18:1687-99
5. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008;2:75-82
6. Oldfield V, Dhillon S, Plosker GL. Tocilizumab. A review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32
7. Jones J, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
8. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32
9. An MM, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010, 66:49-59
10. Bergman GJD, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41
11. Van Vollenhoven RF, Scali JJ, Curtis JR, et al. Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 3.1 years of treatment in long-term extension studies. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology [poster SAT0172]; 16 - 19 June in Rome, Italy; 2010
12. European Medicines Agency. RoActemra (tocilizumab). Summary of Product Characteristics. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000955/WC500054890.pdf [Accessed 25 Augest 2010]
13. Tamaki K, Kogata Y, Sugiyama D, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008;35:114-19
14. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biologic agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl I):i2-29 (Pubitemid 350032626)
15. Van Vollenhoven RF, Keystone EC, Furie R, et al. Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials [abstract 1613]. Arthritis Rheum 2009;60(Suppl):S602
16. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Implications for translational therapeutics. Cancer 2007;110:1911-28 (Pubitemid 350036849)
17. Yamanaka H, Nishimoto N, Inoue E, et al. Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort of Japanese patients and a Japanese population database [abstract OP0228]. Ann Rheum Dis 2007;66(Suppl 2):122-3
18. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and impact of treatment. Semin Arthritis Rheum 2009;38:372-81
19. Nakamura I, Omata Y, Naito M, et al. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol 2009;36:459-60
20. Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2010. [Epub ahead of print]
21. Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol 2009;19:273-4
22. Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol 2010;24:495-6
23. Sugiura F, Kojima T, Oguchi T, et al. A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol 2009;19:199-203
24. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med 2009;48:1307-9
25. Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61
26. Taylor WJ, Weatherall M. What are open-label extension studies for? J Rheumatol 2006;33:642-3
27. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments. How to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008;300:2417-19
28. Littman BH. Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? Arthritis Rheum 2009;60:1565-6
29. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97 (Pubitemid 351392039)
30. Fleischmann R, Burgos-Vargas R, Ambs P, et al. LITHE: tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis patients at 2 years with increasing clinical efficacy over time [abstract 637]. Arthritis Rheum 2009;60(Suppl):S238-9
31. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
32. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80